Generex Biotechnology Corporation announced it would stage the Phase I trial of its cancer immunotherapy in China. The trial will be performed in collaboration with Dr. Daopei Lu and the Beijing Daopei Hospital in Beijing, China. The immunotherapy demonstrated a robust anti-tumor immunity in a variety of mouse tumor models. More details...
Stock Symbols: (NSDQ: GNBT)
Sorry... this feature or article is only available to subscribers.